Bevacizumab in Metastatic Renal Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT02627144
Status
Completed

Conditions

  • Renal Cell Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
  • Interferon alpha-2a — DRUG
    Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.

Study Details

This is a non-interventional, multicenter study to evaluate efficacy and safety of intravenous bevacizumab (Avastin) in combination with interferon alpha-2a immunotherapy for first-line treatment in participants with advanced and/or metastatic renal cell cancer (mRCC) in daily routine.

Key Dates

First listed
Dec 10, 2015
Start date
Jan 31, 2008
Status verified
Jul 2016
Primary completion
Sep 30, 2014
Completion
Sep 30, 2014

Study Design

Enrollment
365 participants (actual)

Arms

  • Arm: Advanced and/or Metastatic RCC participants
    Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.

Primary Outcome Measure

Percentage of Participants With Best Overall Tumor Response [ Time Frame: Baseline until progression or intolerable toxicity, whichever occurred first, assessed up to 6 years ]

Related Studies